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Background: Early recurrence after resection of colorectal liver metastases (CLM) is common. Patients at risk of
early recurrence may be candidates for enhanced preoperative staging and/or earlier postoperative imaging. The
aim of this study was to determine if there are any risk factors that specifically predict early liver-only and systemic
recurrence.
Methods: Retrospective analysis of prospective database of patients undergoing liver resection (LR) for CLM from
2004 to 2006 was undertaken. Early recurrence was defined as occurring within 18 months of LR. Patients were
classified into three groups: early liver-only recurrence, early systemic recurrence and recurrence-free. Preoperative
factors were compared between patients with and without early recurrence.
Results: Two hundred and forty-three consecutive patients underwent LR for CLM. Twenty-seven patients (11%)
developed early liver-only recurrence. Dukes C stage and male sex were significantly associated with early liver-only
recurrence (P < 0.05). Sixty-six patients (27%) developed early systemic recurrence. Tumour size ≥3.6 cm and tumour
number (>2) were significantly associated with early systemic recurrence (P < 0.001).
Conclusions: It is possible to stratify patients according to the risk of early liver-only or systemic recurrence after
resection of CLM. High-risk patients may be candidates for preoperative MRI and/or computed tomography-positron
emission tomography (CT-PET) scan and should receive intensive postoperative surveillance.Background
The liver and lungs are the most frequent sites of distant
metastases from colorectal cancer (CRC). Following diag-
nosis, 50% to 60% of patients with CRC will develop colo-
rectal liver metastasis (CLM) [1], and 11% will develop
pulmonary metastasis [2]. Surgical resection is the most
effective treatment for CRC that has metastasized to the
liver [3] or lung [4]. Indeed, in selected patients, liver
resection (LR) for CLM has yielded a median 5-year
survival rate of 25% to 58% [3,5,6] and a median 5-year
survival of 45% to 60% for solitary liver metastasis [3].
However, recurrence after resection of colorectal liver
metastases is common, developing in the liver remnant* Correspondence: balsin@hotmail.com
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unless otherwise stated.in up to 30% of patients [7,8] and at extra-hepatic loca-
tions in up to 50% [9-12].
Despite surgical resection, the relatively high recur-
rence rate is likely due to occult micro-metastases. Local
and/or systemic recurrence may develop within months
to years after LR [13]. Early recurrence may be due to
aggressive tumour biology, inadequate surgical resection
and/or failure of systemic therapy and may also be an in-
dication of suboptimal pre-operative staging. There are
currently no universally agreed protocols for either pre-
operative imaging before LR or for surveillance postop-
eratively [14]. Contrast-enhanced computed tomography
(CT) is the imaging modality of choice for staging pa-
tients with liver metastases and for postoperative moni-
toring. Magnetic resonance imaging (MRI) has a higher
sensitivity than CT in detecting liver metastases, particu-
larly when used with liver-specific contrast [15], but is
not routinely performed in many centres [16]. Similarly,
the role of fluorodeoxyglucose (FDG) positron emissionThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The timing of liver-only and systemic recurrence following
LR for CLM.
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disease before LR remains unproven [17].
The risk factors for recurrence after LR are well docu-
mented and relate to the biology and stage of the pri-
mary tumour, the burden of liver metastases and the
response to chemotherapy [3,5,18]. Recent studies have
suggested factors that may predict early recurrence after
liver resection for CLM. Vigano et al. have shown that
T3-T4, synchronous CLM and limited resection margins
increase the risk of recurrence [19]. In addition, the same
group showed that adjuvant chemotherapy reduced re-
currence rates. Other authors have suggested that the
number of liver metastases predicts early recurrence
[13]. These particular subgroup of patients may benefit
from enhanced pre-operative staging and/or intensive
post-operative surveillance in the early post-operative
period.
Patients at risk of early recurrence may also benefit
from neoadjuvant or adjuvant chemotherapy. The aim of
this study was to identify predictors of early liver-only or
systemic recurrence after resection of CLM.
Methods
Patients and data collection and statistical analysis
We reviewed our prospectively held departmental data-
base to identify all patients who had undergone LR for
CLM between January 2004 and December 2006 inclu-
sive. Two hundred forty-three patients were identified.
Patients were considered for LR after clinical evaluation
and pre-operative staging with a chest, abdominal and
pelvic CT scan. All patients were discussed within a spe-
cialist hepatobiliary multidisciplinary team meeting. MRI
was performed selectively in patients with advanced pri-
mary tumours (T4 or N2) or synchronous metastases.
CT-PET was performed in selected patients to assess
any suspicious extra-hepatic lesions detected by CT.
After initial LR, patients underwent regular clinical as-
sessment, serial serum CEA measurement and surveil-
lance CT scans at 1 and 2 years postoperatively. In this
study, early recurrence was defined by the presence of
either liver-only or systemic (with or without liver in-
volvement) disease within 18 months after liver resec-
tion. Eighteen months was selected as a cut-off based on
an analysis of the timing and pattern of postoperative re-
currence in the entire cohort. The reason for opting
for this time period is illustrated in Figure 1. Most
liver-only and systemic recurrence occurred with 18months
following LR.
It is unlikely that enhanced preoperative staging (that
is, MRI and/or CT-PET) would detect additional sites of
disease in patients who subsequently develop recurrence
beyond 18 months after surgery. Potential risk factors
for early recurrence were identified including clinical,
radiological and pathological parameters: age, gender,site and nodal status of the primary CRC, the size and
number of hepatic tumours. Pre-operative CEA was not
included in the analysis due to incomplete data. Initially,
for the purposes of analysis, a range of variables was com-
pared between the three study groups (No recurrence/
Liver recurrence/Systemic recurrence). For the continuous
variables, a Kruskal-Wallis test was performed to test for
variations between the three groups. Where this was sig-
nificant, post hoc pairwise tests were performed between
the non-recurrence group and both recurrence groups, in
order to test for significant differences. A similar approach
was applied to the binary variables in which a Fisher’s
exact test was performed on all three groups initially, with
post hoc tests used to compare the non-recurrent patients
with patients in the other two groups. Patient survival was
calculated using Kaplan-Meier estimates. P values <0.05
were considered statistically significant.
Results
In this study, 243 patients underwent LR of CLM with
curative intent between January 2004 and December
2006 inclusive. Table 1 shows the overall demographics
of the study population.
At a median follow-up of 58 months (range 33 to
74 months), 93 patients (38%) developed early recur-
rence (defined as within 18 months of surgery), includ-
ing 27 patients (11%) with liver-only recurrence and 66
patients (27%) with systemic recurrence (with or without
liver recurrence). Thirty-five patients (14%) developed
late recurrence and 115 patients (47%) were recurrence-
free at follow-up (Table 2). Median times to diagnosis of
recurrence in patients with liver-only recurrence and
systemic recurrence were similar: 11 [6-14] vs. 9.5 [6-14]
months (P = 0.841). In patients with early liver-only re-
currence, 19 patients (70%) had treatable lesions (repeat
LR 11, radiofrequency ablation 8), and 8 patients were
suitable for palliative treatment only. Seventeen patients
(26%) with early systemic recurrence were amenable to
further surgery (pulmonary metastasectomy, N = 13) or
ablation (N = 4). Twenty-seven patients (41%) received
Table 1 The overall patient demographics in the study
population
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Colon 57%
Rectum 43%
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were suitable for best supportive care only. Five-year
overall and disease-free survival rates in the entire co-
hort were 47% and 42%, respectively. Median survival in
patients with disease recurrence (liver or systemic) was
6.5 months (range 2 to 26 months). As expected, disease
recurrence was associated with significantly worse over-
all survival (Figure 2).
Analysis of our patient cohort revealed that male pa-
tients and advanced stage primary tumours (Dukes C)were significant risk factors for early liver-only recur-
rence (see Table 3). Early systemic recurrence was more
likely in patients with a high burden of liver metastases
(tumour diameter >3.6 cm or tumour number ≥2.3).
Discussion
In an era of modern chemotherapy, surgical resection of
CLM can be justified and may yield long-term survival
in selected patients [20-22]. However, disease recurrence
after LR is common and negatively impacts on patient
survival [13,18,22]. Disease recurrence presumably re-
flects the presence of viable tumour deposits that are
undetected by conventional pre-operative CT [23]. MRI
is increasingly being utilized to characterize benign and
malignant liver lesions [14,24-26] and appears to be
more sensitive than CT, particularly when used with
liver-specific contrast agents [14]. The potential advan-
tages of MRI over CT are particularly evident in patients
with background hepatic steatosis after chemotherapy
[27]. However, at present, there is insufficient evidence
to justify the routine use of MRI prior to LR for CLM.
Risk factors for early recurrence after LR have been
suggested previously such as multiple (>8) CLM [13]
with recurrence within the liver being the commonest
cause of treatment failure [28]. However, no studies
have identified factors that specifically predispose to
early liver-only or systemic recurrence. Previous multivari-
ate analysis has revealed node positive primary tumours,
advanced T stage, presence of extrahepatic disease,
CEA >200 ng/ml, multiple tumours, tumour size >5 cm
and short disease-free interval as predictors for early re-
currence and poor overall survival [5,18,29,30]. Using this
data, a clinical risk score was created to help predict which
patients will benefit most from surgical intervention [5].
The current study expands these known risk factors by
clearly demonstrating that larger and multiple tumours in-
crease the risk of early systemic recurrence and male gen-
der and advanced CRC predispose to early liver-only
recurrence after LR.
The first aim of our study was to determine if there
are any preoperative risk factors that may predispose pa-
tients to tumour recurrence within the liver remnant
specifically within the early post-operative period. On ana-
lysis, male sex and advanced primary tumours (Dukes C)
increased the risk of early liver-only recurrence. Such pa-
tients may be candidates for pre-operative MRI, and they
may also benefit from enhanced postoperative surveillance.
Early post-operative imaging (CT or MRI) in high-risk pa-
tients may identify liver-only recurrence at an earlier, treat-
able stage, which may potentially influence long-term
survival although there remains no conclusive data from
the available literature. Other groups also investigating the
risk factors for CLM recurrence after LR have failed to
show any affect of gender unlike the reported study [31].
Table 2 Demographics of patients with no recurrence and those with liver-only and systemic recurrence
No recurrence Early liver-only recurrence Early systemic recurrence
(n = 115) (n = 27) (n = 66)
Male–female ratio 1:0.4 1:0.13 1:0.4
Age (years) 65 67 66
(Quartiles) (56 to 71) (65 to 73) (58 to 71)
Primary tumour site CRC (%) Colon 63 71 70
Rectum 37 29 30
Primary tumour stage (%) Dukes A 11 0 4
Dukes B 25 4 22
Dukes C 64 96 74
Chemotherapy after colectomy (%) 92 90 94
Pre-operative staging modality (%) CT 94 96 91
MRI 5 4 7
Other 1 0 2
Post-operative staging modality CT 88 91 87
MRI 10 9 10
Other 2 0 3
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remain unclear.
The second aim of our study was to identify any po-
tential risk factors that predict systemic recurrence spe-
cifically in the early post-operative period. Our data has
indicated that patients with multiple tumours (three or
more) or tumours greater than 3.6 cm are at high risk of
early systemic recurrence. This group of patients is un-
likely to benefit from LR as an isolated strategy and
should be considered for pre-operative CT-PET and sys-
temic chemotherapy. Using this approach, some patients
with detectable FDG avid extra-hepatic disease may be
spared from futile liver surgery [32]. PET/CT produces a
fusion image combining conventional cross-sectional,
anatomical imaging of CT with the biological, functional
imaging of PET [33]. It can be utilized successfully toFigure 2 Overall patient survival in following LR for CLM.identify and stage primary CRC [34] as well as metasta-
ses [33] and has also been used to great effect in the sta-
ging of pancreatic [35] and lung [36] cancers. PET/CT
in CLM patients may be associated with alterations in
patient management in 34% owing to disease upstaging
[37]. Indeed, recent meta-analyses found FDG-PET was
the most sensitive method for detection of liver metasta-
ses and extra-hepatic metastatic disease with sensitivities
of 90% to 92% [15,17]. FDG-PET had a significantly
higher pooled sensitivity and specificity for hepatic dis-
ease and EHD when compared to CT [38]. Moreover,
PET/CT identifies more definitely normal and definitely
abnormal lesions than with PET alone in CRC patients
with improvements in staging and restaging [34]. Indeed,
these changes in staging alter patient management in
25% of patients with the use of 18FDG-PET resulting inTable 3 Analysis of factors predicting liver-only and






(n = 115) (n = 27) (n = 66)
Number of metastases 1 2 2.5*
Median (quartiles) (1 to 2) (1 to 2) (2.3 to 3.1)
Largest tumour size 2.9 2.7 3.9*
Median (quartiles) (2.5 to 3.2) (2.4 to 3.2) (3.6 to 4.2)
Male gender (%) 67 93** 56
Dukes C CRC 64 96** 74
*P < 0.05 relative to no recurrence group; **P < 0.05 relative to no
recurrence group.
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In a recent prospective study comparing 100 CLM pa-
tients staged by conventional techniques with 103 pa-
tients staged with an additional FDG-PET, the rate of
non-therapeutic laparotomies was significantly reduced
in patients having preoperative FDG-PET. [38]. The re-
sults of this study were mirrored by a randomized study
of 150 CLM patients selected for surgical resection by
CT imaging alone or CT plus FDG-PET, which similarly
demonstrated a significantly reduced rate of futile lapar-
otomies [40]. Taken together with previous studies, it
appears that liver recurrence following resection for
colorectal metastasis is associated with T3-T4 disease,
synchronous CLM, limited resection margins, Dukes C
stage and male sex. Systemic recurrence appears to cor-
relate with tumour size and tumour number.
Conclusions
In summary, it is possible to identify patients at high risk
of early liver-only or systemic recurrence after LR for
CLM. Such patients may be candidates for enhanced
pre-operative staging to detect occult metastases and
may also benefit from early post-operative imaging. A
tailored approach to pre-operative staging in patients
with CLM warrants further evaluation in a prospective
study.
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